GlassScriptPhysician profile
Sambit K Barua
NPI 1558350835
$6,690.33
in general payments reported to CMS, 2019-2025
22 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $155 · 2021: $681 · 2022: $636 · 2023: $1,440 · 2024: $1,594 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,676 · Education: $25.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,675.83 |
| Education | $25.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,138.47 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,610.43 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Takeda Pharmaceuticals U.S.A., INC. | $723.15 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $548.58 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $448.16 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $342.67 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $237.01 | 2023-2025 | Omvoh |
| Shionogi INC | $128.82 | 2019-2020 | |
| Redhill Biopharma INC. | $88.66 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Intercept Pharmaceuticals, INC. | $79.55 | 2021-2025 | Ocaliva |
| Organon LLC | $58.68 | 2023-2025 | Renflexis, Hadlima |
| Celltrion USA INC. | $44.85 | 2024 | Zymfentra, Vegzelma |
| Fresenius Kabi USA, LLC | $44.13 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $38.84 | 2024 | |
| Digestive Care, INC. | $33.25 | 2024 | Pertzye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $27.27 | 2022 | |
| Nestle Healthcare Nutrition INC. | $26.55 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $18.25 | 2025 | Suflave |
| Braintree Laboratories, INC. | $16.35 | 2025 | Sutab, Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.70 | 2024 | Cyltezo |
| Amgen INC. | $11.51 | 2021 | |
| Merck Sharp & Dohme LLC | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sambit Barua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.